Thrivent Financial For Lutherans Vor Biopharma Inc. Transaction History

Thrivent Financial For Lutherans

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.1 - $3.35 $342,220 - $545,922	-162,962 Reduced 52.12%	149,690 $317,000
Q2 2023 Aug 14, 2023	SELL	$3.09 - $5.33 $7,901 - $13,628	-2,557 Reduced 0.81%	312,652 $967,000
Q1 2023 May 17, 2023	BUY	$4.68 - $6.96 $39,302 - $58,450	8,398 Added 2.74%	315,209 $1.7 Million
Q4 2022 Feb 08, 2023	BUY	$3.77 - $7.43 $16,584 - $32,684	4,399 Added 1.45%	306,811 $2.04 Million
Q3 2022 Nov 14, 2022	BUY	$3.9 - $5.52 $60,684 - $85,891	15,560 Added 5.42%	302,412 $1.2 Million
Q2 2022 Aug 16, 2022	SELL	$3.89 - $6.44 $73,804 - $122,186	-18,973 Reduced 6.2%	286,852 $1.43 Million
Q1 2022 May 13, 2022	SELL	$6.04 - $12.23 $1,920 - $3,889	-318 Reduced 0.1%	305,825 $1.85 Million
Q4 2021 Feb 16, 2022	BUY	$11.32 - $18.02 $26,545 - $42,256	2,345 Added 0.77%	306,143 $3.56 Million
Q3 2021 Nov 15, 2021	BUY	$12.24 - $20.38 $309,892 - $515,980	25,318 Added 9.09%	303,798 $4.76 Million
Q2 2021 Aug 19, 2021	BUY	$18.65 - $38.78 $13,110 - $27,262	703 Added 0.25%	278,480 $5.19 Million
Q1 2021 May 17, 2021	BUY	$30.96 - $54.08 $8.6 Million - $15 Million	277,777 New	277,777 $12 Million

41.2M

9.3K

100

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $33.1M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.